^
Association details:
| Biomarker: | ALK mutation + TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Analysis of correlations between driver mutations and biomarkers with response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
Published date:
05/19/2021
Excerpt:
One patient with a BRAF mutation and another patient with an ALK mutation had partial responses (PR); both had TMB ≥ 10....In patients with driver mutations, while PD-L1 expression may not be associated with response to immunotherapy, a high TMB level may be a predictive biomarker...
DOI:
10.1200/JCO.2021.39.15_suppl.e21022
